Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.
Curatis licenses corticorelin to Neupharma in CHF 83.5m Japan deal
Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.